Articles Tagged With: SGLT2
-
Are SGLT2 Inhibitors Effective for HFpEF Patients Without Diabetes?
After comparing empagliflozin vs. placebo for patients with heart failure and preserved left ventricular ejection fraction, researchers found no differences in the significant reduction of the primary outcome of cardiovascular death or heart failure hospitalization over 36 months based on whether patients were diabetic.
-
Treatment Indication for Diabetes Drug Expanded to Include Heart Failure
FDA approves empagliflozin to help lower risk of hospitalization, death among heart failure patients.
-
Is Empagliflozin Safe in Combination with a Neprilysin Inhibitor for Heart Failure?
A prespecified subgroup analysis of heart failure patients with reduced ejection fraction who were on neprilysin inhibitors before empagliflozin was administered (vs. those not on neprilysin inhibitors) showed the reduction in mortality and hospital admissions for heart failure was not attenuated by concurrent neprilysin use.